Michael Szarek, PhD, on the Next Steps for Tivozanib in Patients with Advanced RCC
March 1st 2021An analysis revealed that as a third- or fourth-line treatment for advanced renal cell carcinoma, tivozanib significantly increased Q-TWiST compared with sorafenib, primarily through an increase in TWiST.